Sunday, October 21, 2012

Spectrum DD Links


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
"The median PFS and OS were 2.64 and 6.60 months, respectively. Exploratory analysis revealed that disease stabilization rate (complete response plus PR plus SD) in tumors having high and low HR23B histoscores were 58% and 14%, respectively (P = .036). CONCLUSION Epigenetic therapy with belinostat demonstrates tumor stabilization and is generally well-tolerated. HR23B expression was associated with disease stabilization."

    No comments:

    Post a Comment